Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events

v3.22.1
Subsequent Events
3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events

NOTE 12 – SUBSEQUENT EVENTS

On April 4, 2022, the Company entered into a First Amendment (the “First Amendment”) to the K2 Loan and Security Agreement which (a) eliminated requirements that the Term Loans (as defined in the K2 Loan and Security Agreement) amortize prior to the Term Loan Maturity Date (as defined in the K2 Loan and Security Agreement) and (b) revised the K2 Loan and Security Agreement such that the covenant regarding minimum Liquidity (as defined in the K2 Loan and Security Agreement) shall apply for the entire term of the K2 Loan and Security Agreement. A fee of $297,500 was paid by Molecular Templates OpCo, Inc., as the Borrower to K2 HealthVentures LLC, as administrative agent for the Lenders, in connection with the First Amendment.